Supplementary Figure 3 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer

Supplementary Figure 3. Combined use of SHP099 with alectinib, crizotinib or osimertinib Cell viability after treatment with a single agent or a combination of agents relative to the control (set to 1). All drugs were loaded for 96 h. Error bars represent the standard error. *P < 0.01 (one-way ANOVA and the Bonferroni method). S, SHP099; A, alectinib; C, crizotinib; O, osimertinib.